This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: AMZN, MA, AZN, NEE and AMD
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AMZN, MA, AZN, NEE and AMD
Moderna Stock Surges 260% YTD on Coronavirus Vaccine Progress
by Zacks Equity Research
Moderna (MRNA) is making significant progress in development of coronavirus vaccine. The vaccine is currently in phase III study.
AstraZeneca Begins Coronavirus Antibody Combo Phase I Study
by Zacks Equity Research
AstraZeneca's (AZN) AZD7442 is a combination of two coronavirus-neutralizing monoclonal antibodies, AZD8895 and AZD1061.
Tropical Storms Put These Oil ETFs in Focus
by Sweta Killa
Oil price has shown some strength over the past couple of days as the two tropical storms - Marco and Laura - threatened more than half of the production in the Gulf of Mexico and prompted refinery cuts.
5 Sectors Set to Boom on Coronavirus Vaccine Optimism: Top Picks
by Sweta Killa
While the prospect of a COVID-19 treatment will lead to broad-based gains, some investing areas are expected to benefit the most.
Top Analyst Reports for Amazon, Mastercard & AstraZeneca
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com (AMZN), Mastercard (MA) and AstraZeneca (AZN).
Travel & Leisure ETFs Set to Gain on COVID-19 Vaccine News
by Sweta Killa
The vaccine news has infused optimism into the sectors, including cruise lines, airlines, hotel and casino operators, and travel and entertainment-booking companies.
Novavax Begins Enrollment in Phase II Coronavirus Vaccine Study
by Zacks Equity Research
Novavax (NVAX) starts enrolling in the phase II portion of its COVID-19 vaccine study, which is testing the immunogenicity and safety of its candidate NVX-CoV2373 in the United States and Australia.
Stock Market News for Aug 25, 2020
by Zacks Equity Research
The S&P 500 and the Nasdaq hit an all-time high on Monday after news of a potential coronavirus treatment lifted investors' sentiment.
Dow Reclaims 28,000: 5 Stocks Driving the ETF Rally
by Sweta Killa
The Dow Jones Industrial Index ended above 28,000 for the first time in six months.
AstraZeneca Coronavirus Vaccine May Get FDA's Emergency Tag
by Zacks Equity Research
AstraZeneca's (AZN)/Oxford's AZD1222 is in phase II/III study in the UK, Brazil and South Africa with a late-stage study due to start soon in the United States with 30,000 participants.
FDA Grants Emergency Use to Plasma Therapy to Treat Coronavirus
by Kinjel Shah
Convalescent plasma contains antibodies that can fight off the disease faster and prevents COVID-19 patients from getting severely ill.
AstraZeneca's Imfinzi Gets Priority Tag for 4-Week Dosing
by Zacks Equity Research
The FDA grants priority review to AstraZeneca's (AZN) sBLA seeking approval of Imfinzi for a four-week fixed-dose regimen for its approved indications in bladder cancer and non-small cell lung cancer.
Novavax Begins Phase IIb Coronavirus Vaccine Study in South Africa
by Zacks Equity Research
Novavax (NVAX) starts a phase IIb study in South Africa to evaluate the efficacy of its COVID-19 vaccine candidate NVX-CoV2373. Shares rise following this development.
AstraZeneca (AZN) to Supply Coronavirus Vaccine in Europe
by Zacks Equity Research
AstraZeneca (AZN) closes a deal with the European Commission for supplying at least 400 million doses of its COVID-19 vaccine, AZD1222, if approved.
Novavax (NVAX) to Supply Coronavirus Vaccine to UK Government
by Zacks Equity Research
Novavax (NVAX) enters an agreement to provide the UK government with 60 million doses of its COVID-19 vaccine, NVX-CoV2373, if approved.
Pharma Stock Roundup: FDA Approval for Roche's SMA Drug & Other Updates
by Kinjel Shah
Teaser: FDA approves Roche's (RHHBY) new SMA drug, Evrysdi (risdiplam).
Tivity, GrafTech, Moderna, Glaxo and AstraZeneca as Zacks Bull and Bear of the Day
by Zacks Equity Research
Tivity, GrafTech, Moderna, Glaxo and AstraZeneca as Zacks Bull and Bear of the Day
Moderna Up on $1.5B Federal Funding for Coronavirus Vaccine
by Zacks Equity Research
Moderna (MRNA) inks a deal with the U.S. government for supplying 100 million doses of mRNA-1273, its vaccine against COVID-19. Shares rise in pre-market trading.
CytoDyn Reports Top-Line Data From Phase II Coronavirus Study
by Zacks Equity Research
CytoDyn (CYDY) announces top-line results from a phase II study evaluating leronlimab in COVID-19 patients with mild-to-moderate symptoms.
Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes
by Kinjel Shah
The Zacks Large-Cap Pharmaceuticals industry ranks in the bottom 26% of more than 250 Zacks industries.
Drug/Biotech Stock Q2 Earnings Due on Aug 11: VIR and AUPH
by Kinjel Shah
Let us take a look at two small biotech companies, VIR and AUPH, which are gearing up for their earnings release.
Ironwood (IRWD) Q2 Earnings Beat on Solid Linzess Sales
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the second quarter. COVID-19 impacts enrollment in clinical studies.
Moderna (MRNA) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Moderna (MRNA) reports narrower-than-expected second-quarter loss. Shares decline presumably on absence of any new data on coronavirus vaccine candidate.
Ionis (IONS) Q2 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Ionis (IONS) posts narrower-than-expected Q2 loss. Sales miss estimates.